Higher-Dose RT Extends Survival in High-Risk Prostate Cancer

A recent study reported that high-dose radiation, in combination with long-term androgen deprivation therapy (ADT) is linked to significantly improved progression-free, cancer-specific, and overall survival rates in patients with high-risk prostate cancer compared to standard-dose radiation. The GETUG-AFU 18 trial found that those who received high-dose radiation had a 39% reduced risk of death compared to those who received standard-dose radiation. This high-dose treatment also did not lead to additional late urinary tract or gastrointestinal toxicities. These findings suggest that high-dose radiation with long-term ADT should be the standard treatment for high-risk prostate cancer patients. The study also showed that the use of high-dose radiation is likely due to intensity modulated radiation therapy (IMRT). The safety analysis of the treatment showed low and comparable rates of late genitourinary and gastrointestinal toxicities between the study groups. Despite these findings, there are still debates within the medical community over the use of this treatment.

Source link